ADMA Biologics (ADMA)
H.C. Wainwright analyst Jason Kolbert reiterated a Buy rating on ADMA Biologics today and set a price target of $17. The company’s shares closed yesterday at $5.74.
According to TipRanks.com, Kolbert ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -6.2% and a 37.3% success rate. Kolbert covers the Healthcare sector, focusing on stocks such as Cytori Therapeutics Inc, Anavex Life Sciences, and Coherus Biosciences.
ADMA Biologics has an analyst consensus of Strong Buy, with a price target consensus of $13, a 126.5% upside from current levels. In a report released today, Maxim Group also maintained a Buy rating on the stock with a $12 price target.
H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Bellerophon today and set a price target of $3. The company’s shares closed yesterday at $1.10.
“Our price target of $3/share is based on a discounted cash flow analysis (2018-2026) using a 12% discount rate and 2% growth rate, in line with the expected discount and growth parameters of a development-stage drug company. Risks to our investment thesis and target price include: (1) failure in clinical studies; (2) failure to secure regulatory approval; and (3) smaller than anticipated commercial opportunity due to market size, competition and pricing. Bellerophon Therapeutics, Inc.”
According to TipRanks.com, Fein is a 5-star analyst with an average return of 12.3% and a 46.1% success rate. Fein covers the Healthcare sector, focusing on stocks such as Proteostasis Therapeutics Inc, ACADIA Pharmaceuticals Inc, and Strongbridge Biopharma Plc.
Bellerophon has an analyst consensus of Hold.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.